Skip to main content
. 2020 Aug 18;11:1281. doi: 10.3389/fphar.2020.01281

Figure 5.

Figure 5

NLRC5 inhibits inflammation in EESCs (n = 7). (A) Representative western blotting showing 2, 5, and 10 ng/ml of TNF-α all induced NLRC5 expressions in EESCs compared with control group, and the highest protein levels of NLRC5 were reached at 5 ng/ml after 24 h induced by TNF-α treatment (**P < 0.01 vs. control group). (B–D) Representative western blotting, qRT-PCR, and ELISA showing over-expression of NLRC5 by transfection with NLRC5 plasmid significantly inhibited IL-6 and TNF-α expressions when compared with vector group (**P < 0.01 vs. vector group). (E–G) Representative western blotting, qRT-PCR, and ELISA showing inhibition of NLRC5 by transfection with siRNA-NLRC5 significantly promoted IL-6 and TNF-α expression when compared with scrambled-RNAi group (**P < 0.01 vs. scrambled-RNAi group). The expression levels of mRNA were normalized with respect to β-actin and were calculated using the 2-ΔΔCt method. The protein expression levels were quantified by Image J software and normalized to β-actin protein levels. The results are represented as the mean ± SEM from at least three independent experiments.